Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


11.07.2022

1 BMC Gastroenterol
1 Cancer
2 Clin Infect Dis
1 Gastroenterol Hepatol
1 Gastroenterology
2 Hepatology
1 Int J Cancer
1 J Hepatol
1 J Med Virol
4 J Viral Hepat
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Gastroenterol

  1. CHEN JF, Weng WZ, Huang M, Peng XH, et al
    The impact of serum thyroid-stimulation hormone levels on the outcome of hepatitis B virus related acute-on-chronic liver failure: an observational study.
    BMC Gastroenterol. 2022;22:330.
    PubMed         Abstract available


    Cancer

  2. PARIKH ND, Mehta N, Hoteit MA, Yang JD, et al
    Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.
    Cancer. 2022 Jul 7. doi: 10.1002/cncr.34378.
    PubMed         Abstract available


    Clin Infect Dis

  3. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    PubMed         Abstract available

  4. MARATHE G, Moodie EE, Brouillette MJ, Delaunay CL, et al
    Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada.
    Clin Infect Dis. 2022 Jul 5. pii: 6629407. doi: 10.1093.
    PubMed         Abstract available


    Gastroenterol Hepatol

  5. RONCERO C, Buch B, Martin-Sanchez AM, Alvarez-Navares AI, et al
    Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis.
    Gastroenterol Hepatol. 2022 Jun 30. pii: S0210-5705(22)00172.
    PubMed         Abstract available


    Gastroenterology

  6. KIM NJ, Vutien P, Berry K, Ioannou GN, et al
    Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after HCV cure with DAAs in patients with cirrhosis or high FIB-4.
    Gastroenterology. 2022 Jun 28. pii: S0016-5085(22)00681.
    PubMed        


    Hepatology

  7. SINGH SP, Mishra AK, Jindal A
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.
    PubMed        

  8. GUPTA S, Nath P, Anand AC
    Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.
    PubMed        


    Int J Cancer

  9. FU P, Gong B, Li H, Luo Q, et al
    Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34201.
    PubMed         Abstract available


    J Hepatol

  10. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
    PubMed        


    J Med Virol

  11. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    PubMed         Abstract available


    J Viral Hepat

  12. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13731.
    PubMed         Abstract available

  13. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed         Abstract available

  14. PAPATHEODORIDI M, Papachristou E, Moschidis Z, Hadziyannis E, et al
    Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13729.
    PubMed         Abstract available

  15. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed         Abstract available


    PLoS One

  16. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    PubMed         Abstract available

  17. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed         Abstract available

  18. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: